Abstract |
The heptanoyl tripeptide, FK-565 is a biological response modifier with potent therapeutic properties for the treatment of experimental and spontaneous metastases. Doses of FK-565 greater than 5 mg/kg are required for in vivo augmentation of natural killer cells, macrophages, and for therapeutic activity, presumably because FK-565 is a peptide small molecular mass which is rapidly degraded and excreted. Optimal therapeutic activity is observed at approximately 25-50 mg/kg FK-565, administered i.v. three times per week for 4 weeks. In addition to its therapeutic properties, which were consistently greater than the positive control at optimal doses, FK-565 had significant immunoaugmentary properties for natural killer cells, macrophages, and T cells both in vitro and in vivo, suggesting that its therapeutic activity is due to immune augmentation.
|
Authors | J E Talmadge, B Lenz, M Schneider, H Phillips, C Long |
Journal | Cancer immunology, immunotherapy : CII
(Cancer Immunol Immunother)
Vol. 28
Issue 2
Pg. 93-100
( 1989)
ISSN: 0340-7004 [Print] Germany |
PMID | 2521814
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Adjuvants, Immunologic
- Antibiotics, Antineoplastic
- Oligopeptides
- heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine
|
Topics |
- Adjuvants, Immunologic
(pharmacology, therapeutic use)
- Animals
- Antibiotics, Antineoplastic
(pharmacology, therapeutic use)
- Cell Line
- Cytotoxicity, Immunologic
(drug effects)
- Killer Cells, Natural
(drug effects)
- Lymphocyte Culture Test, Mixed
- Macrophage Activation
(drug effects)
- Male
- Mice
- Mice, Inbred C3H
- Mice, Inbred C57BL
- Neoplasm Metastasis
- Neoplasm Transplantation
- Neoplasms, Experimental
(drug therapy, immunology)
- Oligopeptides
(pharmacology, therapeutic use)
- T-Lymphocytes, Cytotoxic
(drug effects)
- T-Lymphocytes, Regulatory
(drug effects)
|